IL-2 production inhibition

Inhibition of IL-2 production refers to the suppression, prevention, or reduction of interleukin-2 (IL-2) synthesis by activated T lymphocytes. IL-2 is a key cytokine that promotes proliferation and survival of T cells, including cytotoxic and helper T cell subsets, and plays a central role in immune defense and immune regulation. Various drugs, endogenous molecules (e.g., prostaglandin E2), and immunomodulatory agents can inhibit IL-2 production by interfering with T cell activation pathways, signal transduction (such as the calcineurin pathway, or Jak-STAT signaling), or by promoting Treg cell development. This process is a critical therapeutic strategy in conditions where immune suppression is desired, such as autoimmune disorders, organ transplantation, and certain inflammatory diseases. Notably, "IL-2 production inhibition" itself is not a receptor, enzyme, or single molecular entity, but an outcome induced via multiple biological mechanisms and drug targets.

Other names

Suppression of IL-2 synthesisinhibition of IL-2 releaseIL-2 synthesis blockade

Inhibition of T cell receptor (TCR) signaling (e.g., calcineurin inhibition by cyclosporine/tacrolimus) Modulation of cytokine signaling (e.g., dexamethasone inhibits Jak-STAT pathway downstream of IL-2 receptor) Increased suppressor T cell activity (induced by PGE2) Blockade of costimulatory signaling or second messengers in T cells